EP-0108A是一种适度选择性BRD4BD2抑制剂,具有潜在的AML瘤抑制作用
Li Li1,2, Hui Zhu2, Shuang Liu2
1Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China.
Anti-cancer drugs
|September 11, 2024
概括
一种新的BRD4抑制剂EP-0108A在临床前模型中显示出抗瘤作用. 这种化合物为癌症治疗提供了有效性和安全性之间的潜在平衡,具有可控的毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性髓性白血病是成年人患的一种流行癌症.
- 一个表观遗传调节剂BRD4,驱动瘤基因表达 (例如c-Myc) 并是一个治疗点.
- 现有的BRD4抑制剂因域选择性而面临毒性或疗效方面的挑战.
研究的目的:
- 开发一种具有平衡有效性和安全性的BRD4抑制剂EP-0108A.
- 评估EP-0108A的抗瘤活性和毒性概况.
主要方法:
- 开发EP-0108A,一种具有中度BD2选择性的BRD4抑制剂.
- 在MV4-11和卡苏米-1异种移植小鼠模型中评估EP-0108A的抗瘤作用.
- 对大鼠和比格尔犬的安全性和毒性进行评估,包括重复剂量研究.
主要成果:
- 在临床前癌症模型中,EP-0108A表现出显著的抗瘤作用.
- 在安全性研究中,该化合物对心脏或呼吸没有显著的不良影响.
- 在老鼠和狗中观察到可逆的血液和胃肠道毒性.
结论:
- EP-0108A为癌症治疗提供了一个有前途的治疗候选药物.
- 抑制剂的平衡选择性可能会减轻之前药物的毒性问题.
- 需要进一步研究EP-0108A作为一种新的癌症治疗药物.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


